| James Paul Arthur, MD | |
|
340 S Willard St, Cottonwood, AZ 86326-4126 | |
| (928) 639-6025 | |
| (928) 634-5604 |
| Full Name | James Paul Arthur |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 40 Years |
| Location | 340 S Willard St, Cottonwood, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588680516 | NPI | - | NPPES |
| 270885 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 15540 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Verde Valley Medical Center | Cottonwood, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Arizona Healthcare Corporation | 3577473362 | 370 |
News Archive
New research can enhance survival of islets transplants and improve treatment of type 1 diabetes. Transplantation of insulin-producing cell islets, so-called islets of langerhans is an appealing strategy for treatment of type 1 diabetes. But it turns out that these are short-lived, and the procedure needs to be repeated.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
Contact precautions, used in addition to the standard precautions, the basic level of infection control applied to all patients, did not limit or prevent the spread of drug-resistant bacteria in non-intensive care unit hospital wards, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
› Verified 8 days ago
| Entity Name | Northern Arizona Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669914552 PECOS PAC ID: 3577473362 Enrollment ID: O20170801003409 |
News Archive
New research can enhance survival of islets transplants and improve treatment of type 1 diabetes. Transplantation of insulin-producing cell islets, so-called islets of langerhans is an appealing strategy for treatment of type 1 diabetes. But it turns out that these are short-lived, and the procedure needs to be repeated.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
Contact precautions, used in addition to the standard precautions, the basic level of infection control applied to all patients, did not limit or prevent the spread of drug-resistant bacteria in non-intensive care unit hospital wards, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Paul Arthur, MD 1200 N Beaver St, Payer Credentialing, Flagstaff, AZ 86001-3118 Ph: (928) 213-6235 | James Paul Arthur, MD 340 S Willard St, Cottonwood, AZ 86326-4126 Ph: (928) 639-6025 |
News Archive
New research can enhance survival of islets transplants and improve treatment of type 1 diabetes. Transplantation of insulin-producing cell islets, so-called islets of langerhans is an appealing strategy for treatment of type 1 diabetes. But it turns out that these are short-lived, and the procedure needs to be repeated.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
Contact precautions, used in addition to the standard precautions, the basic level of infection control applied to all patients, did not limit or prevent the spread of drug-resistant bacteria in non-intensive care unit hospital wards, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
› Verified 8 days ago
Elena Suzanne Shea, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 S Willard St Ste 103, Cottonwood, AZ 86326 Phone: 928-634-9573 Fax: 928-634-0135 | |
Laurel A Mueller, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 51 Brian Mickelsen Pkwy, Community Health Center Of Yavapai, Cottonwood, AZ 86326 Phone: 928-639-8132 | |
Donald E Stephens Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 340 S Willard St, Cottonwood, AZ 86326 Phone: 928-639-6025 Fax: 928-634-5604 | |
Patricia Anne Smith, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 340 S Willard St, Cottonwood, AZ 86326 Phone: 928-639-6025 | |
Marvin L Colvin, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 753 N Main St, Ste. A, Cottonwood, AZ 86326 Phone: 928-634-7470 Fax: 928-639-3280 | |
Dr. Henry H Kaldenbaugh, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 214 S Main St, Cottonwood, AZ 86326 Phone: 928-634-7534 | |
Mary F. Sutter, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 51 S Brian Mickelsen Pkwy, Cottonwood, AZ 86326 Phone: 928-634-6828 Fax: 928-639-8179 |